AIDEVI Product Development Report
AIDEVI NAD+ SUSTAIN Product Development Report
AIDEVI NAD+ SUSTAIN was formulated as an NR-centered cellular wellness system: NR Malate supports NAD+ precursor availability, while L-Ergothioneine, PQQ, Pterostilbene, and Spermidine were selected for complementary antioxidant, mitochondrial, and cellular-maintenance research directions.
This page translates the product development file into a public-facing science overview. It explains the formulation question, ingredient roles, raw-material quality considerations, cell-model findings, 28-day consumer-study observations, testing controls, and the evidence boundaries that matter before making product claims.
- The formula has a clear role architecture: NAD+ precursor support, antioxidant support, mitochondrial wellness, and normal cellular maintenance.
- In a six-hour H9c2 rat cardiomyocyte assay, the complete formula increased intracellular NAD+ versus untreated control cells.
- The same cell assay did not show that the complete formula increased short-term NAD+ more than isolated NR Malate.
- A 28-day open-label consumer study in 30 healthy women observed changes in skin measurement parameters and self-assessment responses.
- The current evidence supports a transparent research story, not disease-treatment, age-reversal, or guaranteed-result claims.
Page Contents
Product Snapshot
AIDEVI NAD+ SUSTAIN is a 5-in-1 enteric-coated capsule formula designed for adults building an NR-centered daily cellular wellness routine. It is not a single-ingredient NR product and should not be positioned as an instant energy product, disease treatment, or anti-aging guarantee.
| Product | AIDEVI NAD+ SUSTAIN |
| Format | Enteric-coated capsules |
| Bottle count | 60 capsules |
| Serving structure | 30 servings based on a 2-capsule daily serving |
| Active ingredients | Nicotinamide Riboside Malate, L-Ergothioneine, PQQ, Pterostilbene, and Spermidine |
| Public evidence purpose | Explain the research rationale and testing record behind the formula while clearly separating findings from limitations. |
The Formulation Question
The development file starts from a practical science question: if the goal is NAD+ support, should a formula focus only on a precursor, or should it also address the cellular environment in which NAD+ is produced and used?
NR, short for Nicotinamide Riboside, is studied as an NAD+ precursor. Human research has shown that repeated NR and pterostilbene administration can increase NAD+-related biomarkers under controlled study conditions, although dose, population, duration, and endpoints differ by study [1]. That evidence supports the use of NR as the formula's central precursor direction.
But an ingredient being central does not mean every supporting ingredient should make the same claim. In this formula, NR Malate is the component directly tied to NAD+ precursor support. Ergothioneine, PQQ, Pterostilbene, and Spermidine were selected to broaden the formula into antioxidant, mitochondrial, and cellular-maintenance research directions.
The key distinction
AIDEVI should not say that all five ingredients directly boost NAD+. A more accurate statement is that NR Malate supports NAD+ precursor availability, while the other ingredients were chosen for complementary cellular-wellness roles.
The Formula Architecture: Make, Protect, Support, Maintain
The strongest public story for NAD+ SUSTAIN is not "five powerful anti-aging ingredients." That is vague and easy to overclaim. The stronger story is a defined architecture: one precursor direction plus four supporting research directions.
| Formula Role | Ingredient | Plain-English Meaning | Claim Boundary |
|---|---|---|---|
| Make | NR Malate | Provides NR, a precursor the body can use in NAD+ biosynthesis. | Does not prove a guaranteed energy or longevity outcome. |
| Protect | L-Ergothioneine and Pterostilbene | Support an antioxidant-focused cellular wellness direction. | Does not mean disease prevention or proven human NAD+ preservation. |
| Support | PQQ | Fits mitochondrial-function and cellular-energy research conversations. | Does not prove new mitochondria are created in users. |
| Maintain | Spermidine | Connects the formula to normal autophagy and cellular-maintenance research. | Does not establish human lifespan extension or age reversal. |
Ingredient Selection Logic
Each active was selected for a specific formulation role. This is where the page should build topical authority: not by saying "premium ingredients," but by explaining what each ingredient is supposed to do inside the formula architecture.
Nicotinamide Riboside Malate: The Precursor Core
NR Malate is the formula's direct NAD+ precursor component. The development report identifies Boncata® NRHM, a crystalline NR Malate raw material selected for stability, low hygroscopicity, powder handling, dissolution characteristics, and taste profile.
The supplied report lists a raw-material purity specification of at least 97%, or at least 99% on a dry basis. That should be presented as a raw-material specification and tied to the relevant certificate of analysis before being used as a finished-product batch claim.
L-Ergothioneine: Antioxidant-Focused Cellular Support
Ergothioneine is a sulfur-containing compound that is transported by SLC22A4/OCTN1 and studied in antioxidant and cellular-stress contexts [2]. It gives NAD+ SUSTAIN a defined antioxidant-support direction.
The development report identifies SIYOMICRO-ERGO® as the selected raw material and lists an HPLC purity specification of 99.9%. The stronger public claim is not that EGT protects every user's NAD+ pool, but that it was selected for antioxidant-focused cellular wellness research.
PQQ: Mitochondrial-Wellness Direction
PQQ has been studied in cell and preclinical models related to mitochondrial function and cellular stress [3]. In this formula, PQQ helps explain why NAD+ SUSTAIN is positioned as a broader cellular-wellness blend rather than a single-precursor capsule.
Pterostilbene: Polyphenol Support
Pterostilbene is structurally related to resveratrol and is studied for antioxidant and metabolic properties. The development file references pharmacokinetic and safety literature, but this page should avoid claiming that pterostilbene is superior for every human use case. Its role is complementary polyphenol support within the antioxidant direction.
Spermidine: Cellular Maintenance and Autophagy Research
Spermidine is a naturally occurring polyamine studied in relation to autophagy, a normal cellular recycling process. Foundational research includes preclinical longevity models [4]. For AIDEVI, the appropriate public framing is cellular-maintenance support, not human life-extension proof.
Raw-Material Quality Considerations
A raw-material story is useful only if it is specific. "High quality" is not a claim. Identity, purity, stability, manufacturing method, lot documentation, and finished-product testing are claims because they can be verified.
| Material | Development Record | How to Communicate It Publicly |
|---|---|---|
| Boncata® NRHM | Crystalline NR Malate selected for stability, lower hygroscopicity, dissolution profile, taste profile, and purity specification. | Use as a raw-material engineering story. Verify patent, NDI, stability, and COA details before making prominent legal or regulatory claims. |
| SIYOMICRO-ERGO® | Synthetic-biology L-Ergothioneine selected for purity, fermentation control, sensory profile, and production efficiency. | Use as an ingredient-quality story. Tie purity and sustainability claims to applicable supplier documentation and batch records. |
Best public-facing rule
Do not let raw-material specifications drift into finished-product guarantees. A raw-material COA supports that material and lot; a finished-product claim needs finished-product documentation.
Cell Assay Findings: What Was Actually Measured?
The cell assay is the most useful credibility asset on the page, but only if interpreted correctly. It tested short-term intracellular NAD+ changes in H9c2 rat cardiomyocytes after a six-hour incubation. It did not test human absorption, long-term use, perceived energy, skin appearance, or safety in people.
| Model | H9c2 rat cardiomyocytes |
| Measurement | Intracellular NAD+ concentration normalized to total cellular protein |
| Method | WST-8 enzymatic cycling method with BCA protein normalization |
| Control group | 14.27 ± 0.18 nmol NAD+ per mg protein |
| Complete formula group | 15.02 ± 0.11 nmol NAD+ per mg protein |
| Reported difference vs control | +0.75 nmol/mg protein, approximately +5.3%; p<0.01 in the supplied development report |
The interpretation that should appear on the page
The complete formula increased intracellular NAD+ compared with untreated control cells in this short-term cell model. The same report found no statistically significant short-term NAD+ difference between the complete formula, isolated NR Malate, and NR Malate plus Pterostilbene. This supports NR Malate as the formula's main NAD+ precursor and keeps the supporting ingredients in their correct complementary roles.
28-Day Consumer Study: What Was Observed?
The supplied development file includes a 28-day open-label, single-arm consumer study in 30 healthy women aged 35 to 50. Participants used the recommended daily serving and completed instrument-based skin measurements at baseline and Day 28.
Study design summary
- Participants: 30 healthy women aged 35-50
- Duration: 28 consecutive days
- Design: Prospective, open-label, single-arm study
- Tools: Cutometer MPA 580, DermaLab Combo-4, and PRIMOS CR
- Limitation: No placebo group, no blinding, small sample, and no long-term follow-up
The study observed changes in skin elasticity, firmness, dermal ultrasound measurements, and wrinkle morphometry during the 28-day period. These data are useful because they are instrument-based, but the study design cannot prove that the formula alone caused the changes.
| Measured Parameter | Observed Day-28 Change | Responsible Interpretation |
|---|---|---|
| Gross skin elasticity, R2 | +16.31%; p<0.001 | Instrument-measured improvement during the study period. |
| F3/F4 elasticity ratio | +11.86%; p<0.001 | A supporting elasticity-related measurement from the same study. |
| Skin firmness, F4 | -18.49%; p<0.001 | Lower F4 was interpreted as firmer skin under the study method. |
| Dermal thickness | +9.85%; p<0.001 | A measured ultrasound change that requires controlled replication. |
| Wrinkle length | -13.34%; p<0.001 | A surface-measurement change observed after 28 days. |
| Wrinkle area | -14.24%; p<0.001 | A study-specific observation, not a guaranteed cosmetic result. |
The report also states that no adverse events, cutaneous hypersensitivity, or gastrointestinal discomfort were reported during the study. That is useful tolerability information for this participant group and duration. It does not establish universal safety for all users, longer use, pregnancy, nursing, medication combinations, or medical conditions.
Quality and Testing Controls
Quality content should answer a buyer's next question: what did AIDEVI check besides ingredient theory? The supplied development file lists cGMP-compliant manufacturing and third-party testing records covering microbial limits, heavy metals, and hormone screening.
| Quality Area | What It Answers | Report Reference in Development File |
|---|---|---|
| Raw-material identity and purity | Whether incoming ingredients match their stated specifications. | Supplier documents and raw-material specifications |
| Cell-model evaluation | Whether the finished formula changed intracellular NAD+ in a short-term H9c2 cell assay. | Shenzhen Siyomicro Bio-Tech report ZKXY-JC-2025123001 |
| 28-day consumer study | Whether skin-related measurements changed during a 28-day open-label study. | Centre Testing International report A2250982523101001C |
| Microbial and heavy-metal testing | Whether tested samples met selected microbial and elemental-safety criteria. | SGS-CDTC report GZF25-0063648-03 |
| Hormone screening | Whether tested samples were screened under the selected hormone-testing method. | SGS-CDTC report GZF26-0000586-01 |
Evidence Boundaries
This is the section most supplement brands avoid. AIDEVI should keep it. It makes the page more credible for sophisticated shoppers and more usable for AI systems that need clear, bounded claims.
- The cell assay does not demonstrate human absorption, bioavailability, perceived energy, skin outcomes, or long-term safety.
- The cell assay did not show that the complete formula was superior to isolated NR Malate for short-term intracellular NAD+ accumulation.
- The 28-day consumer study was open-label and single-arm, so it does not prove causation.
- Ingredient mechanism research does not automatically establish the effect of the finished formula.
- The evidence does not show that NAD+ SUSTAIN reverses aging, extends lifespan, treats fatigue, prevents disease, or guarantees visible results.
- Stronger efficacy questions would require randomized, blinded, placebo-controlled, longer-duration studies.
How This Connects to the Finished Product
The purpose of this page is trust-building, not replacing the product page. For supplement facts, serving directions, purchase options, and routine guidance, readers should continue to the AIDEVI NAD+ SUSTAIN product page.
Readers comparing NAD+ directions can also review AIDEVI NMN 18000 for an nmn-centered routine, or AIDEVI Ergothioneine for an antioxidant-focused cellular wellness direction.
Explore AIDEVI NAD+ SUSTAIN
View the current product format, store availability, and purchasing details through AIDEVI's official store.
Frequently Asked Questions
What is the main idea behind AIDEVI NAD+ SUSTAIN?
The formula uses NR Malate as its NAD+ precursor direction and adds Ergothioneine, PQQ, Pterostilbene, and Spermidine for complementary antioxidant, mitochondrial, and cellular-maintenance research directions.
Did the full formula perform better than NR alone in the cell assay?
No superiority finding should be claimed from the supplied cell assay. The complete formula increased intracellular NAD+ versus untreated control cells, but it was not statistically different from isolated NR Malate for short-term NAD+ accumulation.
Was NAD+ SUSTAIN studied in humans?
The development file includes a 28-day open-label, single-arm consumer study in 30 healthy women aged 35-50. It observed changes in several skin-measurement parameters, but the design cannot prove causation because there was no placebo control or blinding.
Does this report prove anti-aging results?
No. The report supports a research-informed product story, but it does not prove age reversal, lifespan extension, disease prevention, or guaranteed cosmetic results.
How should customers use this information?
Customers should use this page to understand the formulation rationale and evidence limits, then review the product label and consult a healthcare professional before use if pregnant, nursing, taking medication, managing a medical condition, or combining multiple NAD+, antioxidant, or healthy-aging supplements.
Research References
- [1] Dellinger et al. Repeat dose NRPT increases NAD+ levels in humans safely and sustainably. NPJ Aging and Mechanisms of Disease, 2017.
- [2] Höhn et al. Aging in the context of oxidative stress, proteostasis loss and cellular senescence. Redox Biology, 2017.
- [3] Gao et al. PQQ protects mitochondrial function in a premature-senescence cell model. NPJ Aging, 2022.
- [4] Eisenberg et al. Induction of autophagy by spermidine promotes longevity in preclinical models. Nature Cell Biology, 2009.
- Development source: UltraSpec Laboratories. AIDEVI NAD+ SUSTAIN Product Development Report, supplied to AIDEVI.
- Study records listed in the supplied report: Centre Testing International report A2250982523101001C; Shenzhen Siyomicro Bio-Tech report ZKXY-JC-2025123001; SGS-CDTC reports GZF26-0000586-01 and GZF25-0063648-03.
Individual results may vary. Consult a healthcare professional before starting any new supplement, especially if pregnant, nursing, taking medication, managing a medical condition, or following a restricted diet. The research described on this page has limitations and should not be interpreted as medical advice or guaranteed product outcomes. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
